Brian Park, PharmD

Drug Information Specialist https://www.hematologyadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Bleeding Disorders

FDA Extends Review Period for Valoctocogene Roxaparvovec for Hemophilia A

Brian Park, PharmD

March 14, 2023

Valoctocogene roxaparvovec is an investigational adeno-associated virus (AAV) gene therapy.

General Medicine

At-Home Combination Test for COVID-19, Flu Gets Emergency Use Authorization

Brian Park, PharmD

March 3, 2023

The Lucira COVID-19 & Flu Home test is a single-use, nucleic acid amplification test intended for individuals with signs and symptoms consistent with a respiratory tract infection.

Bleeding Disorders

Altuviiio Approved as Once-Weekly Factor VIII Therapy for Hemophilia A

Brian Park, PharmD

February 28, 2023

Altuviiio temporarily replaces the missing coagulation factor VIII needed for effective hemostasis.

Myeloma

Elranatamab Under Review for Relapsed or Refractory Multiple Myeloma

Brian Park, PharmD

February 27, 2023

Elranatamab is a B-cell maturation antigen (BCMA) CD3-targeted bispecific antibody.

Anemia

Crovalimab Noninferior to Eculizumab for Paroxysmal Nocturnal Hemoglobinuria

Brian Park, PharmD

February 13, 2023

Crovalimab achieved disease control in patients with paroxysmal nocturnal hemoglobinuria who have not been previously treated with complement inhibitors.

Leukemia

Brukinsa Gains Approval for Chronic Lymphocytic Leukemia

Brian Park, PharmD

January 25, 2023

The approval was based on data from the phase 3 SEQUOIA and ALPINE studies in patients with CLL/SLL.

Leukemia

AstraZeneca Will Withdraw Leukemia Drug Lumoxiti From US Market

Brian Park, PharmD

January 12, 2023

Lumoxiti was approved by the FDA in September 2018 for the treatment of adults with relapsed or refractory hairy cell leukemia.

patient on ventilator in intensive care unit

General Medicine

Actemra Approved for Treatment of Hospitalized COVID-19 Patients

Brian Park, PharmD

January 6, 2023

Actemra (tocilizumab) is an interleukin-6 receptor antagonist.

General Medicine

Certain Detect COVID-19 Tests Recalled Due to Risk of False Negative Results

Brian Park, PharmD

January 3, 2023

The recall affects a total of 11,102 Detect tests.

Lymphoma

Lunsumio Approved for Relapsed or Refractory Follicular Lymphoma

Brian Park, PharmD

December 29, 2022

Lunsumio is a first-in-class CD20xCD3 T-cell engaging bispecific antibody that targets CD20 on the surface of B cells and CD3 on the surface of T cells.

Next post in Lymphoma